ALIM Alimera Sciences Inc

Price (delayed)

$3.58

Market cap

$25.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$63.68M

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or ...

Highlights
Alimera Sciences's gross profit has decreased by 11% YoY but it has increased by 2.5% from the previous quarter
The revenue has declined by 8% year-on-year but it rose by 2.7% since the previous quarter
Alimera Sciences's quick ratio has shrunk by 78% YoY and by 34% QoQ
The equity is down by 47% since the previous quarter

Key stats

What are the main financial stats of ALIM
Market
Shares outstanding
7.01M
Market cap
$25.09M
Enterprise value
$63.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.18
Earnings
Revenue
$54.06M
EBIT
-$12.83M
EBITDA
-$10.15M
Free cash flow
-$14.7M
Per share
EPS
-$2.67
Free cash flow per share
-$2.1
Book value per share
-$2.58
Revenue per share
$7.73
TBVPS
$4.86
Balance sheet
Total assets
$43.43M
Total liabilities
$61.51M
Debt
$44.14M
Equity
-$18.08M
Working capital
-$4.25M
Liquidity
Debt to equity
-2.44
Current ratio
0.88
Quick ratio
0.73
Net debt/EBITDA
-3.8
Margins
EBITDA margin
-18.8%
Gross margin
85.5%
Net margin
-34.1%
Operating margin
-22.7%
Efficiency
Return on assets
-37%
Return on equity
N/A
Return on invested capital
-25.1%
Return on capital employed
-136.2%
Return on sales
-23.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALIM stock price

How has the Alimera Sciences stock price performed over time
Intraday
3.77%
1 week
-6.64%
1 month
-32.68%
1 year
-26.94%
YTD
-30.21%
QTD
-29.53%

Financial performance

How have Alimera Sciences's revenue and profit performed over time
Revenue
$54.06M
Gross profit
$46.24M
Operating income
-$12.28M
Net income
-$18.43M
Gross margin
85.5%
Net margin
-34.1%
The operating income is down by 13% since the previous quarter
Alimera Sciences's gross profit has decreased by 11% YoY but it has increased by 2.5% from the previous quarter
ALIM's operating margin is down by 10% QoQ
The revenue has declined by 8% year-on-year but it rose by 2.7% since the previous quarter

Growth

What is Alimera Sciences's growth rate over time

Valuation

What is Alimera Sciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.18
The EPS has contracted by 6% from the previous quarter
The equity is down by 47% since the previous quarter
The stock's P/S is 54% less than its 5-year quarterly average of 1.0 and 34% less than its last 4 quarters average of 0.7
The revenue has declined by 8% year-on-year but it rose by 2.7% since the previous quarter

Efficiency

How efficient is Alimera Sciences business performance
ALIM's ROIC is down by 17% from the previous quarter
Alimera Sciences's return on assets has decreased by 15% QoQ
The ROS has contracted by 3.5% from the previous quarter

Dividends

What is ALIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALIM.

Financial health

How did Alimera Sciences financials performed over time
Alimera Sciences's total assets is 29% less than its total liabilities
Alimera Sciences's quick ratio has shrunk by 78% YoY and by 34% QoQ
The current ratio has dropped by 77% year-on-year and by 32% since the previous quarter
The debt to equity has plunged by 108% YoY but it has grown by 31% from the previous quarter
The equity is down by 47% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.